Immunotherapy of superficial bladder tumors: preliminary results with ImmuCyst--BCG Connaught, Toronto.
A clinical study has been started in 1991 with ImmuCyst (BCG Connaught) as a secondary prophylaxis in urothelial superficial bladder tumors (SBT) patients. Till now 31 patient have been entered into the trial and the results seem to be promising. Only 2 patients were excluded from the study. Side-effects did not extend in average the data quoted in literature and were easily managed. There were 4 recurrences confirmed by cystoscopy. Urinary infection was treated in 7 cases with current chemotherapeutic drugs.
Hanus
M
M
Urocentrum CK, Prague, Czech Republic.
Matousková
M
M
Verner
P
P
Hyrsl
L
L
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D005334:Fever / Q000209:etiology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
C087507:BCG Connaught; D001500:BCG Vaccine